James Morrison was named President of Ensysce Biosciences, Inc., succeeding Lynn Kirkpatrick. As of November 6, 2026, Ensysce Biosciences, Inc. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from March 30, 2026 to November 4, 2026, naming 1 appointment and 1 departure (Form 8-K, August 6, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Ensysce Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-11-04
- · In / out: Out · Person: Lynn Kirkpatrick · Role: President · 8-K, 2026-08-06
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-03
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-03-30
Ensysce Biosciences, Inc. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-03-30 to 2026-11-04. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Ensysce Biosciences, Inc. files it.
Also on the record for Ensysce Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 20, 2026 | Form D, private offering | $77.20M sold | Form D page | Source |
| August 18, 2026 | Stake report, Schedule 13D/A, by Bob Gene Gower | 6.1% of the class | 5%+ stakes | Source |
| August 12, 2025 | Stake report, Schedule 13G/A, by Adage Capital Management, L.P. | 3.15% of the class | 5%+ stakes | Source |
| April 25, 2025 | Form D, private offering | $2.20M sold | Form D page | Source |
| April 14, 2025 | Form D, private offering | $1.10M sold | Form D page | Source |
Selling to them or working with them? See who runs Ensysce Biosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Ensysce Biosciences, Inc. and the records around it.
Ensysce Biosciences, Inc. elsewhere on the record
- Company profile and every filing Aug 2026
- Form D filing Aug 2026
- 5%+ stake filings Aug 2026
- Form D filing Apr 2025
- Who owns it
Companies that share a holder
- Adage Capital Management, L.P. also filed stake reports on 136 other companies: ACP Holdings Acquisition Corp. (Aug 2026), AmperCap Acquisition Company (Aug 2026), Aura Biosciences, Inc. (Aug 2026)
Watch Ensysce Biosciences, Inc.
Get an email when Ensysce Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Ensysce Biosciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ensysce Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ensysce Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-04 | Reported | not named in the filing | 8-K, 2026-11-04 | ||
| 2026-08-06 | Out | President | 8-K, 2026-08-06 | ||
| 2026-08-06 | In | President | 8-K, 2026-08-06 | ||
| 2026-04-03 | Reported | not named in the filing | 8-K, 2026-04-03 | ||
| 2026-03-30 | Reported | not named in the filing | 8-K, 2026-03-30 |
Who leads Ensysce Biosciences, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- President: Lynn Kirkpatrick, departure reported (filed 2026-08-06). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Ensysce Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Ensysce Biosciences, Inc. (free up to 3)
Find people with the same kind of experience as the President at Ensysce Biosciences, Inc., with the record behind each one.
Find candidates like President at Ensysce Biosciences, Inc.Every change, in the filing's words
Reported
Ensysce Biosciences Inc. (the "Company") has been advised by Mr. Will Chang, a member of the Company's Board of Directors, that he intends to resign as a Director of the Company following the next annual meeting of stockholders (the "Annual Meeting").
- The Annual Meeting has been scheduled for December 14, 2026.
- Mr. Chang has not provided a writing concerning his resignation or a date of resignation.
- On October 29, 2026, our Chief Executive Officer, Dr. Lynn Kirkpatrick, age 69, agreed that she would assume the title of Chief Operating Officer of the Company immediately following the Annual Meeting in connection with relinquishing her title of Chief Executive Officer.
- If the Annual Meeting is delayed, both her assumption and relinquishment will be delayed.
- As previously reported, immediately following the Annual Meeting, the Company's President, Mr. James Morrisson, will assume the title of Chief Executive Officer.
- Dr. Kirkpatrick has also agreed that she will execute an amendment to her September 14, 2021 employment offer letter with the Company (the "Executive Employment Agreement") to document the change in title and state that Dr. Kirkpatrick agrees that her acceptance of the position of Chief Operating Officer will not trigger the obligations of the Company to pay severance pursuant to the Executive Employment Agreement.
- The Executive Employment Agreement is described in the Company's Annual Report on Form 10-K for year ended December 31, 2025 under "Item 10.
Departing: Lynn Kirkpatrick, President
Resignation of Lynn Kirkpatrick as President and Appointment of James Morrison as President and Director Pursuant to the Merger Agreement, on August 5, 2026, Lynn Kirkpatrick resigned from her position as President of the Company, effective immediately upon the Closing.
Appointed: James Morrison, President
Appointment of James Morrison as President and Director Pursuant to the Merger Agreement, on August 4, 2026, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed James Morrison as President and as a director of the Company effective immediately upon the Closing and appointed Mr. Morrison as Chief Executive Officer effective upon approval of the Meeting Proposals.
- Dr. Kirkpatrick will continue to serve as the Company's Chief Executive Officer until stockholder approval of the Meeting Proposals.
- James Morrison is the Founder of Cy and served as President of Cy from October 2019 until the closing of the Merger and as its Chief Executive Officer from 2021 until the closing of the Merger.
- Mr. Morrison founded Cy to develop innovative therapies for neurological and neuropsychiatric disorders and led the company's scientific, financing and corporate development strategies.
- Previously, Mr. Morrison worked in the commodities trading and financial services industries.
- Mr. Morrison holds a Bachelor of Civil Law degree from the University of Oxford.
Reported
On April 1, 2026, Ensysce Biosciences Inc. (the "Company") received a resignation notice, dated and effective April 1, 2026, from Curtis Rosebraugh, a member of our Board of Directors.
- Until his resignation, Dr. Rosebraugh served as a member of the Nominating and Corporate Governance Committee, a committee of the Board of Directors.
Reported
On March 24, 2026, Ensysce Biosciences Inc. (the "Company") received a resignation notice, dated and effective March 24, 2026, of Lee Rauch, a member of our Board of Directors.
- Until her resignation, Ms. Rauch served as a member of the Audit Committee and Compensation Committee and as the chairperson of the Nominating and Corporate Governance Committee, all committees of the Board of Directors.
- As previously disclosed, the Company is considering strategic alternatives for its business.
- In furtherance of this objective, to retain three managers and its Chief Financial Officer, through this period, which the Company believes is necessary to maintaining its enterprise value, the Compensation Committee determined to recommend to the Board of Directors to put into place three-month severance packages for these managers and increase Mr. Humphrey's (CFO) existing retention package from 6 months to 9 months.
- The packages only apply to the extent that in a strategic deal these parties are not retained as employees in such transaction or for a period of one year following, agree to a full release of claims against the Company which may be legally released by such party and re-confirm their restrictive covenants following termination.
- The total cost of these measures is approximately $205,475.
- Ms. Rauch disagreed with the packages and voted against them on March 23, 2026.
- Ms. Rauch had previously expressed other disagreements with actions considered by the Board of Directors.
- The Board of Directors approved the packages on March 27, 2026.
Ensysce Biosciences, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Ensysce Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.